



IL-7 pathway controls human T cell homing to the gut and culminates in inflammatory bowel disease mucosa

Lyssia Belarif, L. Kermarec, V. Daguin, Mary C., R. Danger, Kucik A., T. Macdonald, G. Blancho, P. Naveilhan, Bernard Vanhove, et al.

► To cite this version:

Lyssia Belarif, L. Kermarec, V. Daguin, Mary C., R. Danger, et al.. IL-7 pathway controls human T cell homing to the gut and culminates in inflammatory bowel disease mucosa. FOCIS 2017, Jun 2017, Chicago, United States. [inserm-02161048](#)

HAL Id: [inserm-02161048](#)

<https://inserm.hal.science/inserm-02161048>

Submitted on 20 Jun 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.


L. Belarif^{1,2,3}, L. Kermarec⁴, V. Daguin^{1,2}, C. Mary^{1,2,3}, R. Danger^{1,2}, A. Kucik⁵, T. MacDonald⁵, G. Blancho^{2,3}, P. Naveilhan⁴, B. Vanhove^{1,2,3}, N. Poirier^{1,2,3}

¹Ose Immunotherapeutics, Nantes, France; ²Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, Nantes, France;

³Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France

⁴INSERM, UMR 913, Nantes F-44035, France; ⁵Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK.


Introduction



Interleukin-7 (IL-7) is a limiting and non-redundant non-classical cytokine produced essentially by epithelial and stromal cells which regulates T-lymphocytes homeostasis. Almost all conventional mature T lymphocytes express the IL-7 receptor (IL-7R), with a particular exception for naturally-occurring regulatory T-cells (Tregs), constituting a rare opportunity to selectively target pathogenic effectors while preserving natural regulators. The signaling networks perpetuating chronic inflammatory bowel disease in man remain unclear. While in mice IL-7 is known to play a role in systemic inflammation, here we found that IL-7 specifically in humans controls $\alpha 4/\beta 7$ integrin expression and imprints gut-homing specificity on T cells.

Results

I- IL-7 controls human effector, but not regulatory T lymphocyte $\alpha 4/\beta 7$ integrin expression




❖ ITGA4/ITGB7, two integrins implicated in the migration of T cells into the gut, are up-regulated by human recombinant IL-7 (rhIL-7) on effector ($CD4^+CD25^+CD127^{hi}$) but not on regulatory T cells (Tregs; $CD4^+CD25^{high}CD127^{low}$).

❖ Up regulation of ITGA4/ITGB7 on effector ($CD4^+CD25^+CD127^{hi}$) T cells is blocked by anti-IL-7R antibodies.

❖ Induction of pSTAT5 in response to IL-7 was observed in T cell and in Treg cells, demonstrating that in spite of low CD127 expression level, Tregs are able to respond to IL-7.


II- Anti-IL-7Ra delays colon inflammation in GVHD humanized mice model




❖ GVHD was induced after infusion of 50.10⁶ human PBMC in NSG mice. Anti-IL7Ra mAb significantly prolonged survival. Strikingly, colon inflammation and human T-cell infiltration in the colon were abolished, without impact on other target tissue of GVHD (intestine, liver and lung).

❖ Acute colitis was induced by intrarectal TNBS/Ethanol administration in humanized mice reconstituted with human CD34⁺ cord blood hematopoietic stem cells. Anti-IL-7Ra mAb prevented colitis with an efficacy similar to Vedolizumab (anti- $\alpha 4/\beta 7$ integrin mAb).

III- Anti-IL-7Ra prevents acute colitis in humanized mice model




IV- IL-7/IL-7R mRNA pathway is accumulated in colon biopsies from UC and CD patients and correlates with treatment-refractory disease



❖ IL-7/IL-7R pathway mRNA expression is significantly increased in the involved colon of CD and UC patients in comparison with uninvolvled biopsy from same patients or Non-IBD controls.


❖ IL-7R α mRNA expression is correlated to ITGA4/ITGB7 mRNA expression in UC and CD patients : (ITGA4 : $p < 0,0001$; ITGA4 : $p < 0,0001$ and ITGB7 : $p < 0,0001$; ITGB7 : $p < 0,0001$).



❖ 21 genes from the IL-7 signaling pathway were re-analyzed from a transcriptomic study of colon biopsies from UC patients. This IL-7 signature segregates into three distinct blocs according to the clinical status. Principal Component Analysis (PCA) of this IL-7 mucosal signature in UC patients displayed a clear and distinct separation between responders versus non-responder patients. IL-7R α micro-array values discriminated UC patients with inflamed versus non-inflamed mucosa (ROC analysis: AUC = 96.9%).

V- Anti-IL7Ra mAb decreases ex-vivo IFNg production by UC colon biopsies

❖ Colon biopsies from inflamed area of UC patients (n=10) were cultured ex-vivo for 24 hours. These tissues spontaneously release proinflammatory cytokines such as IFNg (130 \pm 19 pg/ml). Anti-IL7Ra mAb applied at 10 μ g/ml in this organ culture assay significantly decreased inflammation as measured by IFNg secretion level.



Conclusion

- ❖ IL-7 controls $\alpha 4/\beta 7$ integrin expression in human effector T lymphocytes, but not in Tregs
- ❖ Anti-IL7Ra mAb decreases specifically colon inflammation in humanized mice models
- ❖ Anti-IL7Ra mAb decreases IFNg production in human organ culture assay
- ❖ Transcripts of the IL-7 pathway accumulate in UC biopsies and correlate with absence of response to treatments